230 related articles for article (PubMed ID: 34793138)
1. Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies.
Zafar A; Hasan M; Tariq T; Dai Z
Bioconjug Chem; 2022 Jun; 33(6):1011-1034. PubMed ID: 34793138
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
Peng S; Xiao F; Chen M; Gao H
Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
[TBL] [Abstract][Full Text] [Related]
5. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
6. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
7. Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment.
Sun K; Yu J; Hu J; Chen J; Song J; Chen Z; Cai Z; Lu Z; Zhang L; Wang Z
Acta Biomater; 2022 Aug; 148():230-243. PubMed ID: 35724919
[TBL] [Abstract][Full Text] [Related]
8. Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy.
Li J; Luo Y; Pu K
Angew Chem Int Ed Engl; 2021 Jun; 60(23):12682-12705. PubMed ID: 32671893
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Engineering Nanomedicines for Second Near-Infrared Photothermal-Combinational Immunotherapy.
Wang F; Zhu J; Wang Y; Li J
Nanomaterials (Basel); 2022 May; 12(10):. PubMed ID: 35630880
[TBL] [Abstract][Full Text] [Related]
10. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
[TBL] [Abstract][Full Text] [Related]
11. Thermal immuno-nanomedicine in cancer.
Yang Z; Gao D; Zhao J; Yang G; Guo M; Wang Y; Ren X; Kim JS; Jin L; Tian Z; Zhang X
Nat Rev Clin Oncol; 2023 Feb; 20(2):116-134. PubMed ID: 36604531
[TBL] [Abstract][Full Text] [Related]
12. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
Sun B; Hyun H; Li LT; Wang AZ
Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.
Gao S; Yang X; Xu J; Qiu N; Zhai G
ACS Nano; 2021 Aug; 15(8):12567-12603. PubMed ID: 34339170
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology in the arena of cancer immunotherapy.
Asadujjaman M; Cho KH; Jang DJ; Kim JE; Jee JP
Arch Pharm Res; 2020 Jan; 43(1):58-79. PubMed ID: 31956965
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives.
Chen Y
J Control Release; 2023 Apr; 356():14-25. PubMed ID: 36805873
[TBL] [Abstract][Full Text] [Related]
16. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
[TBL] [Abstract][Full Text] [Related]
17. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Martin JD; Cabral H; Stylianopoulos T; Jain RK
Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
[TBL] [Abstract][Full Text] [Related]
18. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine-mediated optimization of immunotherapeutic approaches in cervical cancer.
Venkatas J; Singh M
Nanomedicine (Lond); 2021 Jun; 16(15):1311-1328. PubMed ID: 34027672
[TBL] [Abstract][Full Text] [Related]
20. Light-responsive nanomedicine for cancer immunotherapy.
Kang W; Liu Y; Wang W
Acta Pharm Sin B; 2023 Jun; 13(6):2346-2368. PubMed ID: 37425044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
